Poor Correlations in the Levels of Pathogenic Mitochondrial DNA Mutations in Polar Bodies versus Oocytes and Blastomeres in Humans  by Gigarel, Nadine et al.
REPORT
Poor Correlations in the Levels of Pathogenic
Mitochondrial DNA Mutations in Polar Bodies
versus Oocytes and Blastomeres in Humans
Nadine Gigarel,1,5 Laetitia Hesters,2,5 David C. Samuels,4 Sophie Monnot,1 Philippe Burlet,1
Violaine Kerbrat,3 Fre´de´ric Lamazou,3 Alexandra Benachi,3 Rene´ Frydman,3 Josue´ Feingold,1
Agnes Rotig,1 Arnold Munnich,1 Jean-Paul Bonnefont,1 Nelly Frydman,2 and Julie Steffann1,*
Because the mtDNA amount remains stable in the early embryo until uterine implantation, early human development is completely
dependent on the mtDNA pool of the mature oocyte. Both quantitative and qualitative mtDNA defects therefore may negatively impact
oocyte competence or early embryonic development. However, nothing is known about segregation of mutant and wild-type mtDNA
molecules during human meiosis. To investigate this point, we compared the mutant levels in 51 first polar bodies (PBs) and their
counterpart (oocytes, blastomeres, or whole embryos), at risk of having (1) the ‘‘MELAS’’ m.3243A>G mutation in MT-TL1 (n ¼ 30),
(2) the ‘‘MERRF’’ m.8344A>G mutation in MT-TK (n ¼ 15), and (3) the m.9185T>G mutation located in MT-ATP6 (n ¼ 6). Seven out
of 51 of the PBs weremutation free and had homoplasmic wild-type counterparts. In the heteroplasmic PBs, measurement of themutant
loadwas a rough estimate of the counterpartmutation level (R2¼ 0.52), and highmutant-load differentials between the two populations
were occasionally observed (ranging from –34% toþ34%). Themutant-load differentials between the PB and its counterpart were higher
in highly mutated PBs, suggestive of a selection process acting against highly mutated cells during gametogenesis or early embryonic
development. Finally, individual discrepancies in mutant loads between PBs and their counterparts make PB-based preconception diag-
nosis unreliable for the prevention of mtDNA disorder transmission. Such differences were not observed in animal models, and they
emphasize the need to conduct thorough studies on mtDNA segregation in humans.Mitochondrial DNA (mtDNA) is a maternally inherited,
small, circular molecule located in the mitochondria.
The mtDNA content remains stable during the first days
of embryonic development, until mtDNA replication
resumes, after implantation in the uterus.1 The abundance
of mtDNA in the mature oocyte (z300 000 mtDNA copy
number) is therefore crucial for early embryonic develop-
ment. Qualitative and quantitative mtDNA defects have
been reported in fertilization failures,2,3 oocyte maturation
defects,4,5 and impaired murine postimplantation embry-
onic development.6 Yet how mtDNA segregates during
oogenesis remains largely unknown. A mitochondrial
genetic ‘‘bottleneck,’’ with only a small number of mtDNA
genomes giving rise to the genotype of the offspring, is
thought to occur during female gametogenesis.7–11 It
causes the fixation of newmtDNA variants, such that dele-
terious mutations are either lost from the maternal line or
reach very high levels and cause a severe disease in a few
generations. In humans, data collected from primary
oocytes and early embryos carrying mtDNA mutations
have suggested that the bottleneck occurs at the end of
gametogenesis.12–16 The bottleneck size may be mutation
specific,12–16 and it would depend on individual parame-
ters.16 No data on mtDNA segregation during the late
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and second polar body (PB) and the corresponding oocyte
for both a polymorphism17 and a deletion,18 suggesting
that mtDNA molecules segregate randomly at this stage.
Taking advantage of our preimplantation genetic diag-
nostic (PGD) service, we investigated mtDNA segregation
during human meiosis by measuring heteroplasmy levels
of three different pathogenic mtDNA mutations in 51 first
PBs and their counterparts (oocytes or preimplantation
embryos). Significant mutant-load differences were found
between PBs and counterparts, with a negative correlation
at high mutant loads. Our results clearly differ from those
in murine models, outlining the necessity of conducting
mtDNA segregation studies in humans.
Three couples at risk of transmitting a pathogenic
mtDNA mutation were referred for PGD and signed an
informed consent for themselves and their embryos. This
study was approved by the National Ethics Committee
from the French Biomedical Agency. The m.3243A>G
mutation inMT-TL1 (MIM 590050), was found at a hetero-
plasmic state (around 25% in blood, urinary tract, and
buccal cells) in the unaffected female partner of couple 1.
Her second child had encephalopathy, with stroke-like
episodes, seizures, and ataxia, consistent with the diagnosis
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mutation load was 60% in cultured skin fibroblasts from
the proband. The couple had previously experienced two
terminations of pregnancy for fetuses with a mutation
load above 60%. Couple 2 requested PGD when the
mother’s brother passed away from myoclonic epilepsy
with ragged-red fibers (MERRF syndrome [MIM 545000]).
The female partner suffered from occasional myoclonic
jerks, carried the m.8344A>G mutation in MT-TK (MIM
590060) , and had mutant loads of 75%, 85%, and 95%
in blood, urinary pellet, and buccal cells, respectively. The
first daughter of couple 3 presented in the first year of life
with cerebellar ataxia and proximal tubulopathy. MRI
showed symmetric lesions in the basal ganglia andhyperin-
tensities in the cerebellum. A partial decrease of the ATP
synthase activity was found on a skeletal muscle sample
(40%) and was subsequently ascribed to the m.9185T>C
mutation inMT-ATP6 (MIM 516060), with a 95%mutation
load in skeletal muscle, urine, blood, and buccal cells.
The proband’s mother was found to have the mutation in
blood (25% mutant load), urinary tract (14%), and buccal
cells (17%).
PGD cycles were carried out via a standard in vitro fertil-
ization (IVF) procedure in couples 1 (3 cycles), 2 (1 cycle),
and 3 (1 cycle). Oocytes were retrieved by transvaginal
ultrasound-guided aspiration. The zona pellucida was
pierced with the use of a noncontact 1.48 mm diode laser
system (Fertilase, MTM Technology), and the first PB was
carefully aspirated from 57 ovulated metaphase II oocytes
(33, 16, and 8 oocytes for patients with m.3243A>G,
m.8344A>G, and m.9185T>C mutations, respectively).
Fertilization by intracytoplasmic sperm injection resulted
in 38 embryos, and their evaluation at day 4 or 5 enabled
classification of ‘‘arrested’’ embryos (14 embryos contain-
ing fewer than 6 cells at day 3 or not continuing embryonic
cleavage after the biopsy) or ‘‘developing’’ embryos
(n¼ 24). A total of 28 out of 38 embryos containing at least
six blastomeres were biopsied on day 3 after injection, as
previously described.19 Overall embryos were either trans-
ferred (n ¼ 8) or collected (n ¼ 30) on day 3 or days 4–5.
Unfertilized oocytes (n ¼ 13) were analyzed separately.
Oocytes, blastomeres, and overall embryos were rinsed in
a drop of PBS supplemented with 0.1% polyvinyl alcohol
(Sigma Aldrich, France) under a binocular microscope
with the use of a mouth-controlled, finely pulled glass
pipette. Cells and embryos were deposited in 3 ml of lysis
buffer20 under visual control with an inverted microscope
and were lysed by heating for 10 min at 65C. For each
sample, a small volume of rinsing medium was transferred
similarly and used as a negative template.
The mutations were quantitated via semiquantitative
fluorescent PCR and restriction endonuclease digestion,
as previously reported.15,16,21 Such tests have been shown
to be suitable for mutant-load assessment over a large
range of mtDNA copy-number templates (from 102 to
106 molecules), with good repeatability (5 2%).16,21
Single-cell and embryonic DNA were amplified in a 25 ml
reaction volume containing 0.2 mM of each primerThe Am(Eurogentec, Angers, France) (Table S1 available online)
and 23 Master Mix (12.5 ml, QIAGEN Multiplex PCR Kit).
Denaturation was carried out at 95C for 15 min, fol-
lowed by 30 cycles of 30 s at 94C, 90 s at corresponding
annealing temperature (Table S1), and 1 min at 72C,
and terminated with a final extension of 30 min at
60C. Cross hybridization of oligonucleotide primers to
genomic DNA was ruled out by PCR amplification on
mtDNA-less Rho0 cells.22 The m.3243A>G amplification
products (10 ml) were submitted to HaeIII digestion.16
The m.8344A>G mutation was quantitated via an Allele
Creating Restriction Site (ACRS) method based on forward
primer modification to create a Bgl1 restriction site in the
mutant allele.23 Taking advantage of the suppression of
the MnlI restriction site by the m.9185T>G mutation, we
submitted corresponding PCR products (10 ml) to Mnl1
digestion for 2 hr at 37C. Digested products (1 ml) were
suspended in a mix containing formamide (15 ml,
genetics-analysis grade, Applied Biosystems) and ROX
400HD (0.3 ml, Applied Biosystems). After denaturation
for 2 min at 95C, samples were electrophoresed in an
automated ABI3130 genetic analyzer (Applied Biosystems).
Results were analyzed with the Genescan and Genotyper
software (Applied Biosystems). The mutant load was calcu-
lated by dividing the mutant peak area by the sum of the
mutant and wild-type peak areas. The mutant-load-detec-
tion threshold was 2% for the three mutations.
Unequal partitioning of mitochondria between two
daughter cells of vastly different sizes (inheriting around
1% and 99% of the ooplasm, respectively)24 generates
a genetic drift (the so-called ‘‘sampling error’’). A reliable
statistical estimate of this drift can be calculated, but it is
necessarily based on the standard assumption that the
mtDNAmolecules drawn into the PB are randomly distrib-
uted and sampled from the oocyte and that the sample size
is much smaller than the mtDNA content of the oocyte.
The sampling error, which is a function of the hetero-
plasmy rate (p) and the sample size (Nsample, in this case
the number of mtDNA molecules within the PB), was
assessed as 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pð1 pÞ=Nsample
p
with a 95% confidence
interval. Since we could not experimentally ascertain the
amount of mtDNA in the PB because of technical limita-
tions, the sampling error was estimated over a range of
possible Nsample values. Mean values are reported as
mean5 2 standard errors of themean (SEM). Comparisons
of mean values were performed with the use of a two-tailed
t test assuming unequal variances, calculated in Excel
2007.
Successful amplification was achieved in 51 of 57 PBs
(amplification rate 89%). A total of seven PBs were found
to be mutation-free (six and one from the patients with
m.3243A>G and m.9185T>G mutations, respectively), as
were their corresponding oocytes (n ¼ 3) or embryos
(n¼ 4). Among the heteroplasmic PBs (n¼ 44), the propor-
tion ofmutantmtDNA ranged from2% to 95% (mean 50%,
median 53%). The corresponding mutant loads, tested
on oocytes (n ¼ 10), whole embryos (n ¼ 28), or twoerican Journal of Human Genetics 88, 494–498, April 8, 2011 495
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Figure 1. Comparison of Mutation Level between First Polar
Bodies and Their Counterparts
Values are shown for 3243 (black circle), 8344 (white circle), and
9185 (black star).
The curves show the 95% confidence interval for a sampling
error calculated by 2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pð1 pÞ=Nsample
p
, in which Nsample is the
mtDNA copy number in the polar body. The dotted line and the
full line have been calculated for two values of Nsample (100 and
10 mtDNA copy number, respectively). The maximum sampling
error occurs at p ¼ 0.5. Seven PBs and counterparts were wild-
type homoplasmic.
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Figure 2. Apparent Influence of the Heteroplasmy Rate on the
Correlation between PB and Counterpart Mutant Loads
The values shown are means 5 2 SEM of the difference between
the counterpart and the polar body mutant loads, calculated
from 34 and 17 PBs carrying less than or over 60% mutant loads,
respectively.blastomeres (transferred embryos,n¼6), ranged from5%to
95% (mean 48%, median 53%; Figure 1). Themeanmutant
load was 37% (5 27%) and 44% (5 26%) in ‘‘arrested
embryos’’ and ‘‘developing embryos,’’ respectively.
The mutant load of each PB was then compared to its
counterpart value (Figure 1). In only half of the cases
(n ¼ 27 of 51), the PBs and their counterparts had similar
mutant loads (5 10%). In particular, homoplasmic wild-
type PBs were constantly associated with homoplasmic
wild-type counterparts (n ¼ 7). By contrast, in the remain-
ing half of the cases, the first PBs differed from their
corresponding oocytes or embryos. Indeed, 13 PBs had
mutant loads 11% to 34% higher than their counterparts,
whereas 11 PBs had mutant loads 13% to 34% lower
than their counterparts. These differences were observed
for the three mutations (Figure 1). A poor correlation in
the levels of mutant mtDNA in PBs and their counterparts
was therefore observed (coefficient of correlation R2 ¼
0.68, p < 0.0001 for a linear fit). The coefficient of correla-
tion was even lower when only heteroplasmic PBs were
considered (R2 ¼ 0.52, p < 0.0001 for a linear fit). Consid-
ering that the mtDNA amount sampled from the ooplasm
to the PB could account for the differences in hetero-
plasmy levels between the two cells, a statistical estimation
of the mtDNA copy number in PBs was made. The spread
of the observed variations was consistent with a very
low mtDNA copy number in PBs (largely ten molecules;
Figure 1).496 The American Journal of Human Genetics 88, 494–498, April 8, 2At higher values of PB mutations, the mutation load
appeared generally higher in the PB than in its counterpart
(Figure 1). The PBs were then split into two groups: below
and above a 60%mutation rate. In the first group (n ¼ 34),
the mean difference between the counterpart and the PB
mutant loads was 3.5%5 5% (Figure 2). The average differ-
ence, however, raised to 11.8% 5 7.8% in the second
group (n ¼ 17; Figure 2). The difference between the two
groups (high versus low mutated PBs) was shown to be
significant with the use of a two-tailed t test (p value ¼
0.0023).
Here, we explored the mtDNA segregation during the
last stage of oogenesis by comparing the ratios of mutated
versus wild-type mtDNA populations in the first PB and
in its counterpart (oocyte, or blastomere, and/or whole
embryo) for three pathogenic mtDNA mutations. This
study shows that the human first PB is not predictive of
the egg mutant load, precluding the use of PB testing for
the diagnosis of mtDNA disorders. Preconception diag-
nosis (PCD), based on the first PB25 and/or second PB
testing,26 is routinely applied to nuclear gene disorders,
in countries where cleavage-stage embryo selection is
banned, or in couples declining potential embryo discard-
ing. It was therefore considered as an attractive diagnostic
procedure for mtDNA disorders. By fixing the mutant-load
threshold under which an embryo is transferred at 30%,
a first-PB-based decision would have led to the transfer of
four embryos carrying mutant loads over 40% and to the
discarding of five embryos with mutant loads less than
30%, giving a predictive positive value of the PB test at
0.84 but a negative predictive value at 0.63. The first PB
is thus not suitable as a diagnostic material, unless the
purpose of PCD is the selection of ‘‘mutation free’’ oocytes.
The mechanism for unequal partitioning of mitochon-
dria between PB1 and the oocyte is unclear. Under the
random-sampling hypothesis, we have computed that
only the very low number of ten mtDNA molecules011
directed to the PB could explain the different mutant loads
between human PBs and their oocytes or embryos. This
estimate is two orders of magnitude less than that from
a previous report, mentioning an mtDNA copy number
of approximately 1000 in ten human first PBs fromhealthy
women.27 Thus, mtDNA copy number could be lower in
mutant than in wild-type PBs, due to some unknown bio-
logical process impacting the mtDNA amount during
the course of gametogenesis. Very little is indeed known
about mtDNA turnover during the human gametogenesis
and early embryonic development,28 but a dramatic effect
of a small increase in mutant load over the mtDNA copy
number has been reported in a human placenta.29
Another, more likely, hypothesis is that the above estimate
of the mtDNA copy number based on the sampling error
mathematical modeling is not fully reliable, owing to
a nonrandom distribution of mtDNA populations in the
primordial oocyte and therefore a nonrandom segregation
between the two daughter cells.
Moreover, we observed that themutant-load distribution
between PBs and ooplasm is apparently influenced by the
mutant load in the PBs (Figure 2). The mutation levels
were indeed significantly lower in the oocytes or embryos
than in the PBs (by 12% on average) at high mutant
loads (> 60%), whereas they were not significantly lower
at lower mutant-load values. This observation suggests
a purifying effect against highly mutated cells acting at
some stage of gametogenesis or early embryonic develop-
ment, possibly resulting from a replicative advantage to
wild-type DNA.30 This selection process would conceivably
counterselect highly mutated oocytes, whose subsequent
embryonic development would be compromised by the
respiratory chain defect.6 Yet, we did not observe any corre-
lation betweenmutant loads and early embryonic develop-
ment (developing versus arrested embryo), at least under
the mutation rates of 70%, 90%, and 54% for m.3243A>G,
m.8344A>G, and m.9185T>G, respectively.
It is worth noting that the results of the few similar
studies in mice are quite different. A close correlation
between PBs and their counterparts was indeed found for
an mtDNA polymorphism (correlation coefficient at
0.99)17 and an mtDNA deletion (correlation coefficient at
0.95).18 These discrepancies between these previous
reports in mouse models and the present one in humans
raise several issues. One can hypothesize an influence of
mtDNA point mutations versus neutral polymorphisms
or large rearrangements on meiotic mtDNA segregation,
irrespective of species. One can also hypothesize that the
processes governing mtDNA segregation during meiosis
differ between humans and mice. Given that the perinu-
clear redistribution ofmitochondria during oocyte matura-
tion is similar in mice and humans,31 species specificity of
the mitochondrial trafficking could be considered.
Whatever their physiological bases, such apparent
discrepancies between the animal studies and ours have
to be kept in mind, especially in the context of preimplan-
tation or preconception diagnoses.32 These results empha-The Amsize the limits of animal models and the subsequent need
to conduct mtDNA segregation studies in humans before
selecting a reproductive option for patients carrying
mtDNA mutations.Supplemental Data
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article online at http://www.cell.com/AJHG/.Acknowledgments
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